Recombinant multi-species DEFB104B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine DEFB104B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
Defensins form a family of antimicrobial and cytotoxic peptides made by neutrophils. Defensins are short, processed peptide molecules that are classified by structure into three groups: alpha-defensins, beta-defensins and theta-defensins. All beta-defensin genes are densely clustered in four to five syntenic chromosomal regions. Chromosome 8p23 contains at least two copies of the duplicated beta-defensin cluster. This duplication results in two identical copies of defensin, beta 104, DEFB104A and DEFB104B, in head-to-head orientation. This gene, DEFB104B, represents the more telomeric copy. [provided by RefSeq, Oct 2014]
The Alternative Names of target: BD-4,Beta-defensin 104,Beta-defensin 4 (BD-4,DEFB-4,DEFB104B,Defensin,beta 104,hBD-4,hBD-4)

Target products collectionGo to DEFB104B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE0857-Ag-1/ GM-Tg-hg-SE0857-Ag-2 Human DEFB104B protein Human
GM-Tg-rg-SE0857-Ag-1/ GM-Tg-rg-SE0857-Ag-2 Rat DEFB104B protein Rat
GM-Tg-mg-SE0857-Ag-1/ GM-Tg-mg-SE0857-Ag-2 Mouse DEFB104B protein Mouse
GM-Tg-cynog-SE0857-Ag-1/ GM-Tg-cynog-SE0857-Ag-2 Cynomolgus/Rhesus macaque DEFB104B protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE0857-Ag-1/ GM-Tg-felg-SE0857-Ag-2 Feline DEFB104B protein Feline
GM-Tg-cang-SE0857-Ag-1/ GM-Tg-cang-SE0857-Ag-2 Canine DEFB104B protein Canine
GM-Tg-bovg-SE0857-Ag-1/ GM-Tg-bovg-SE0857-Ag-2 Bovine DEFB104B protein Bovine
GM-Tg-equg-SE0857-Ag-1/ GM-Tg-equg-SE0857-Ag-2 Equine DEFB104B protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE0857-Ag-1/ GM-Tg-hg-SE0857-Ag-2; GM-Tg-rg-SE0857-Ag-1/ GM-Tg-rg-SE0857-Ag-2;
GM-Tg-mg-SE0857-Ag-1/ GM-Tg-mg-SE0857-Ag-2; GM-Tg-cynog-SE0857-Ag-1/ GM-Tg-cynog-SE0857-Ag-2;
GM-Tg-felg-SE0857-Ag-1/ GM-Tg-felg-SE0857-Ag-2; GM-Tg-cang-SE0857-Ag-1/ GM-Tg-cang-SE0857-Ag-2;
GM-Tg-bovg-SE0857-Ag-1/ GM-Tg-bovg-SE0857-Ag-2; GM-Tg-equg-SE0857-Ag-1/ GM-Tg-equg-SE0857-Ag-2
Products Name DEFB104B protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name DEFB104B
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine DEFB104B protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.